Article
Henlius CEO scouts for US PD-1 partner amid Fosun unit's pivot to innovative drugs from biosimilars
Rating:
0.0
Views:
82
Likes:
1
Library:
1
With a Chinese approval of PD-1 inhibitor serplulimab in March, Fosun Pharma's Shanghai Henlius Biotech officially kicked off its transformation into an innovative biopharma company. | With a Chinese approval for PD-1 inhibitor serplulimab in March, Fosun Pharma's Henlius officially kicked off its transformation into an innovative biopharma company.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value